Axio Biosolutions

Chitosan-based first-aid dressing that stops moderate-to-severe bleeding in 2-3 minutes.

Controls both arterial and venous bleeding, deploys rapidly under stress, and remains effective in hypothermic bleeding.

MaxioCel accelerates healing and comfort for chronic wounds such as diabetic foot ulcers and pressure ulcers.

Ambulance services, first responders, emergency departments, trauma centers, paramedics, plus industrial and household first-aid/vehicle safety kits.

Combat medics, field/battlefield hospitals, special forces, and paramilitary units; India's armed forces are a major customer.

Percutaneous coronary intervention, electrophysiology, interventional radiology and cath-lab settings needing rapid vascular-access hemostasis.

Patients with pressure ulcers, diabetic foot ulcers, venous leg ulcers, cavity wounds and post-operative surgical wounds.

200+ distributor partners across 50+ countries on six continents.

Direct supply to the Indian Armed Forces and paramilitary forces.

Sold to hospitals and emergency services in India and internationally.

Pilot and clinical studies underpinning its biomaterial products (2014-2016 phase of its own growth timeline).

Runs its own captive, certified manufacturing facility rather than outsourcing production.

Pursues FDA 510(k), CE and other approvals to unlock regulated markets.

22+ granted patents underpinning its chitosan-based hemostatic and wound-care technology.

State-of-the-art manufacturing facility in Ahmedabad holding FDA, EU and GMP certification.

De facto supplier of hemostatic dressings to the Indian armed forces, including BSF and NSG.

Academic advisors from Harvard Medical School/MIT, Stanford University Medical Center, and IIT-Gandhinagar.

Axio Biosolutions Private Limited is a wholly owned Indian subsidiary of Boston-based Advamedica Inc.

Revenue from sales of its hemostatic and wound-care device portfolio; standalone revenue was ₹19.9 Cr in FY24.